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Objective: To evaluate the role of three cartilage-derived biomarkers on osteoarthritis (OA): urinary C-
terminal telopeptide (uCTX-II), serum cartilage oligomeric protein (sCOMP), and serum MMP degraded
type II collagen (sC2M).
Subjects and methods: Samples from 3582 individuals from the Rotterdam Study, the Genetics osteo-
Arthritis and Progression (GARP), the Chingford Study and the TwinsUK cohort were assayed using
enzyme-linked immune sorbent assays. Log10 of concentration levels were correlated with risk of hip,
hand and knee OA, hip and knee OA severity and incidence, and progression of knee OA, adjusting for
age, gender and body mass index (BMI). Results were meta-analysed to assess overall signiﬁcance.
Results: After adjusting for covariates, sCOMP was associated with knee OA and hip and knee OA inci-
dence. Furthermore, sC2M was associated with knee OA incidence and progression. After adjustment for
multiple tests (Bonferroni P < 0.002) only the association between sCOMP and knee OA remained sig-
niﬁcant (odds ratio (OR) ¼ 3.26 (95%CI 1.63e10.1) P ¼ 0.0008 for each standard deviation (SD) increase in
biomarker levels). Levels of uCTX-II were signiﬁcantly associated with risk of hand, hip and knee OA,
progression and incidence of knee OA. A receiver operating characteristics (ROC) analysis showed a
consistent improvement in prediction of knee OA progression from an average area under the curve
(AUC) is 0.646 for age, sex and BMI alone to an AUC ¼ 0.668 including uCTX-II for prediction.
Conclusions: uCTX-II is the most informative biochemical marker for prediction of OA. Both sCOMP and
C2M showed some association with OA, thus indicating that they are descriptive of disease activity.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.to: A.M. Valdes, Academic
iences Bld, Nottingham City
ottingham.ac.uk (A.M. Valdes).
ternational. Published by Elsevier LIntroduction
Osteoarthritis (OA) is the most common joint disorder, and its
prevalence is expected to climb as the age of the population in-
creases [http://www.who.int/chp/topics/rheumatic/en/]. A hin-
drance to developing disease modifying drugs has been thetd. All rights reserved.
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severe disease and there is a need for biomarkers that enable early
diagnosis of OA. The use of cartilage-derived biomarkers to
examine direct processes of cartilage degradation and synthesis are
increasingly being used to examine clinically relevant aspects of
OA. The degradation of cartilage can in some part be attributed to
an elevated proteolytic activity, which results in the release of
protein speciﬁc tissue fragments, neo-epitopes, that have been
investigated as biomarkers of joint disease1. A validated example of
neo-epitope biomarkers are those released following cleavage of
type II collagen by MMPs, which reﬂect cartilage degradation.
Among these biomarkers are serumMMP degraded type II collagen
(sC2M)2 and urinary C-terminal telopeptide (uCTX-II)3. Circulating
levels of serum cartilage oligomeric protein (sCOMP), a marker of
cartilagemetabolism, have also been reported to be associated with
disease progression4e6. Hunter and co-workers found that baseline
serum COMP was an independent predictor of cartilage loss by MRI
in 137 patients followed up for 30 months4. A series of type II
collagen and aggrecan-derived biomarkers were evaluated in this
study; however, only COMP showed a signiﬁcant association to
cartilage with an adjusted odds ratio (OR) of 6.35 (range 1.4e29.7)
for each standard deviation (SD) increase in biomarker levels. C2M
is also thought to reﬂect cartilage degradation2 and it was recently
reported that serum levels were highly elevated in OA, Rheumatoid
Arthritis (RA) as well as Ankylosis Spondylitis (AS) and that the
diagnostic utility of that biomarker was high (area under the curve
(AUC) 0.87, P < 0.0001)7. However more data is needed to fully
understand the information which C2M as a biomarker provide.
Of the three markers mentioned above, uCTX-II is the one best
validated so far. uCTX-II was originally described by Christgau et al.8
and has since been evaluated in more than 50 clinical studies. A
large number of studies have associated this index with long-term
structural progression of joint damage in both RA and OA. The ﬁrst
large-scale, longitudinal study of this marker was reported in 2004
based on a follow-up of 1235 subjects originating from the Rot-
terdam9 prospective study of men and women (>55 years of age).
Those individuals who had baseline CTX-II levels in the highest
quartile, had a 6-fold (95% CI range; 1.2e31) increased risk for
radiographic progression (joint space narrowing (JSN) < 2 mm) of
knee OA. A similar OR for hip OA progressionwas 8.4 (95% CI range;
1.0e73) for those having JSN of less 1.5 mm. The data support the
use of a single biochemical marker for identiﬁcation of patients at
high risk for rapid progression of joint destruction.
One problem that has affected biomarker studies has been the
use of small sample sizes and the use of case-control designs with
cases being recruited from secondary care settings. Moreover
different biomarker studies have used different outcome measures
and/or focused on different joints. These factors make it difﬁcult to
evaluate the value of cartilage based biomarkers for clinical use.
In this study, as part of the TREAT-OA consortium, we have
combined data from three large population-based cohorts and a
familial study of OA with hand, knee and hip X-rays, three of them
with longitudinal data. The total sample size of over 3582 in-
dividuals measured for three separate cartilage based biomarkers
enables to assess the role of biomarkers on prevalence, incidence
and progression of OA and to assess the prognostic value of these
biomarkers.
Subjects and methods
Serum COMP, C2M and urinary CTX-II measurements
Serum COMP (COMP, AnaMar, Göteborg, Sweden) and urinary
CTX-II (CartiLaps, IDS, Paris, France) were measured according to
manufacture in the Rotterdam, Genetics osteoArthritis andProgression (GARP), TwinsUK and Chingford studies. Serum C2M
wasmeasured in the studiesusinganovel assaydevelopedbyNordic
Bioscience as described by Bay-Jensen et al.2. All three assays were
measured using enzyme-linked immunosorbent assays based on a
monoclonal antibody. Intra- and inter-assay CV (%) were below 10%.The cohorts
Chingford Study
This study is a prospective population-based longitudinal cohort,
which includes women derived from the age/sex register of a large
general practice in North London. The study design and rationale
have been described elsewhere in detail10. The Guy’s St. Thomas’
Trust and theWaltham Forest Trust ethics committees approved the
study protocol. After study procedures were explained to partici-
pants, written informed consent was given by each participant. OA
was classiﬁed radiological using standard X-rays of the pelvis,
thoracolumbar spine, hands and weight-bearing knees11.TwinsUK
The study participants were white monozygotic and dizygotic
twin pairs from the TwinsUK adult twin registry, a group used to
study the heritability and genetics of age-related diseases12. These
unselected twins were recruited from the general population
through national media campaigns in the United Kingdom. Ethics
approvalwasobtained fromtheGuy’s andSt. Thomas’Hospital Ethics
Committee. Written informed consent was obtained from every
participant. The radiographs were taken between 1995 and 200012.
Anteroposterior extended-viewweight-bearing radiographs of both
knees were obtained at baseline and follow-up using the same pro-
tocol anda tube-to-ﬁlmdistanceof100cm13. Pelvic radiographswith
the subject in the supine anteroposterior position, with a standard
tube-to-ﬁlmdistance of 100 cmand the feet positioned in 15 degrees
of internal rotationwere obtained12. Radiographs of bothhandswere
takenwith a standard posteroanterior view.GARP study
The GARP study from Leiden, the Netherlands, consists of 192
sibling pairs concordant for clinical and radiographically (K/L score)
conﬁrmed OA at two or more joint sites among hand, spine (cer-
vical or lumbar), knee or hip14. Written informed consent was ob-
tained from each subject as approved by the ethical committees of
the Leiden University Medical Center. Conventional radiographs of
the hands (dorso-volar), knees (posterior-anterior (PA) in weight-
bearing semiﬂexed and lateral), hips (PA), lumbar (PA and lateral),
and cervical spine (anterior-posterior, lateral, and transbuccal)
were obtained from all participants. They were taken in a standard
manner with a ﬁxed ﬁlm focus distance and a ﬁxed joint position.
Radiographs of the knees were taken using the ﬁxed ﬂexion radi-
ography14. Baseline were analogue ﬁlms and were digitized using a
ﬁlm digitizer at a resolution corresponding to a pixel size of 100 m.
Radiographs at 6-years follow-up were obtained digitally. Random
controls (N¼720) were partners of the offspring of the Leiden
longevity study15. Radiographs were scored in pairs (baseline-6
year) blinded for patient characteristics by consensus opinion of
two experienced readers using the OARSI atlas2. Osteophytes and
JSN were each graded 0e3 in the tibiofemoral knee and hip joints.
Intraclass correlation coefﬁcients (ICC) for intrareader reproduc-
ibility based on random samples of 20 radiographs were very good
(at least 0.88 in the tibiofemoral knee joints and 1.00 in the hips).
New knee or hip prosthesis on radiograph was scored as having
increase in JSN score of 1. Progression was deﬁned as described in
detail previously10.
Table I
Descriptive statistics of study cohorts
Study cohort GARP Rotterdam Chingford TwinsUK
Sample size 392 1403 753 1034
Age (SD) 59.9 (7.86) 63.2 (6.57) 53.9 (5.91) 55.7 (7.57)
BMI (SD) 27.0 (4.78) 27.1 (3.88) 25.3 (3.88) 24.6 (4.16)
%-Females 80% 56% 100% 100%
Knee OA (controls/all
cases/KL  3)
238/147/59 1084/262/55 522/231/86 661/280/66
Hip OA (controls/all
cases/KL  3))
287/78/17 1237/131/43 634/91/21 593/66/14
Hand OA (controls/cases) 282/110 1131/218 391/260 593/238
Knee OA non
progressors/progressors
316/76 1150/122 528/222 232/82
Knee OA non
incident/incident
N/A 1017/91 510/178 188/61
Hip OA non
incident/incident
N/A 1245/42 666/58 N/A
Log10 CTX-II (SD) 2.31 (0.26) 2.31 (0.23) 2.28 (0.25) 2.29 (0.24)
Log10 COMP (SD) 1.05 (0.12) 1.03 (0.10) 0.98 (0.15) 1.02 (0.13)
Log10 C2M (SD) 1.67 (0.34) 0.49 (0.17) 0.56 (0.23) 0.45 (0.13)
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The Rotterdam Study is a population-based prospective cohort
study ongoing since 1990 to study determinants of chronic
disabling disease16. The Rotterdam Study consists of three sub-
populations. The Rotterdam Study I (RSI) is the ﬁrst cohort of
7983 persons living in the Ommoord district of Rotterdam in the
Netherlands. All subjects were aged 55 years and older and
recruitment started in 1990. The Rotterdam Study II (RSII) started in
1999 when 3011 participants moved into the study since they
became 55 years of age or moved into the study district. A further
extension, the Rotterdam Study III (RSIII), was initiated in 2006 and
to date 3829 participants, aged 45e54 years, are included in this
study. The medical ethics committee of Erasmus University Medical
School approved the study and written informed consent was ob-
tained from each participant. Weight-bearing anteroposterior ra-
diographs of the knee and hip were obtained at 70 kV, a focus of 1.8,
and a focus to ﬁlm distance of 120 cm, applying a Fuji HighTable II
Fixed effect meta-analysis results. OR refer to a log10 unit for each one of the biochemica
value corresponds to P ¼ 0.002, values under this threshold are highlighted in bold
Univariate
TRAIT Biomarker OR 95%CI
Hand OA risk C2M 1.50 (1.02e2.30)
COMP 7.29 (3.8e49.11)
CTX-II 11.20 (7.78e113.91)
Hip OA C2M 1.28 (0.62e2.7)
Incidence COMP 8.26 (1.16e64.9)
CTX-II 5.75 (2.38e30.8)
Hip OA risk C2M 1.33 (0.76e2.4)
COMP 6.87 (2.55e43.6)
CTX-II 6.78 (3.97e42.6)
Hip OA severity C2M 1.42 (0.43e3.47)
COMP 2.60 (0.26e9.86)
CTX-II 4.82 (1.42e22.0)
Knee OA C2M 1.74 (1.02e3.09)
Incidence COMP 9.92 (3.12e89.7)
CTX-II 2.29 (1.55e5.07)
Knee OA C2M 1.94 (1.23e3.69)
Progression COMP 11.0 (3.99e109.)
CTX-II 3.15 (2.23e9.5)
Knee OA risk C2M 1.54 (1.04e2.41)
COMP 12.1 (6.36e133.)
CTX-II 10.0 (7.01e91.4)
Knee OA C2M 0.93 (0.52e1.97)
Severity COMP 5.96 (2.53e33.1)
CTX-II 9.23 (5.61e77.8)Resolution G 35  43 cm ﬁlm9,17. Standard anteroposterior radio-
graphs of both hands were taken18. For the current study, data was
available for 1311 individuals of RS-II, with a mean follow-up time
of 4.1 (SD 0.58) years.Standardisation of the radiographic OA traits
Standardisation of radiographic assessment for all four cohorts
has been previously described19.
Eight different OA outcomes were considered for the present
study:
 Knee OA prevalence: Knee (K/L  1) vs Knee (K/L  2)
 Knee OA severity: Knee (KL ¼ 2) vs Knee (K/L  3)
 Hip OA prevalence: Hip (K/L  1) vs Hip (K/L  2)
 Hip OA severity: Hip (K/L ¼ 2) vs Hip (K/L  3)
 Hand OA: presence of either both ﬁnger or thumb OA in both
hands
 Incident knee OA: knee K/L< 2 at baseline and K/L 2 at follow-
up, non incident K/L < 2 at both baseline and follow-up
 Incident hip OA ¼ hip K/L < 2 at baseline and K/L  2 at follow-
up vs non incident ¼ K/L < 2 at both baseline and follow-up
 Knee OA progression any K/L at baseline (including K/L < 2),
progressor if K/L at follow-up was higher than at baseline, non
progressor otherwise.
Statistical methods
All concentration values were log10-transformed Logistic regres-
sion analyses were carried out on all traits without adjustment (uni-
variate) for each of the traits. In addition, the regression adjustments
were made for age, sex and body mass index (BMI) (multivariate
analysis). Summary statistics (the regression coefﬁcient beta and its
standard error) for each cohort for each outcome for all three
biomarkermeasurementswere thenmeta-analysedusingﬁxedeffect
models. For selected traits, that showed a signiﬁcant association
overall random effect, meta-analysis was also performed. The “meta”l markers. Multivariate analyses are adjusted for age, gender and BMI. Bonferroni P-
Multivariate
P-value OR 95%CI P-value
0.1914 1.19 (0.78e2.13) 0.42
0.0213 1.86 (0.91e3.68) 0.09
1.1E-09 5.01 (3.36e23.5) 2.2E-15
0.50 1.69 (0.69e3.59) 0.25
0.0351 7.25 (0.97e51.3) 0.05
1.0E-04 4.89 (1.7e22.5) 0.0033
0.32 1.12 (0.63e2.51) 0.69
1.4E-04 2.68 (0.96e7.36) 0.06
2.3E-12 4.33 (2.38e17.6) 1.6E-06
0.56 1.41 (0.41e3.52) 0.59
0.41 2.27 (0.18e8.41) 0.52
0.0114 4.59 (1.14e20.4) 0.0317
0.0423 1.95 (1.16e3.75) 0.0117
1.0E-04 5.85 (1.74e32.0) 0.0043
3.5E-05 1.74 (1.14e3.0) 0.0104
0.0042 1.69 (1.05e2.87) 0.0311
3.5E-06 4.07 (1.37e15.8) 0.0114
8.0E-11 2.73 (1.77e7.18) 5.1E-06
0.0307 1.29 (0.85e2.07) 0.23
3.6E-14 3.26 (1.63e10.1) 8.0E-04
7.2E-37 5.72 (3.88e30.5) 7.0E-19
0.82 0.75 (0.4e0.82) 0.37
4.5E-05 1.45 (0.57e3.2) 0.43
1.4E-18 5.72 (3.33e30.5) 2.6E-10
A COMP and  risk of knee OA
0.2 0.5 1 2 5 10 100
3.25 (1.63, 6.49)
TwinsUK 1.41 (0.42, 4.69)
Rotterdam 10.24 (2.02, 51.78)
GARP 2.94 (0.44, 19.64)
Chingford 4.10 (1.29, 12.99)
fe summary 
I2=24% p<0.26
B CTX-II and risk of knee OA
1 2 5 10 100
re summary 4.13 (1.94, 8.80)
fe summary 
I2=84% p<0.0003
2.69 (2.12, 3.46)
TwinsUK 1.87 (1.38, 2.53)
Rotterdam 8.81 (4.05, 19.15)
GARP 4.22 (2.10, 8.50)
Chingford 5.12 (2.41, 10.87)
odds ratio
odds ratio
p= 0.0002
p= 7 x 10[-19]
p= 0.0008
Fig. 1. Forest plot of study-speciﬁc estimates and summary OR estimates and 95% conﬁdence intervals (95%CIs) for the association between (A) serum COMP and prevalence of knee
OA (B) urinary CTX2 and prevalence of knee OA. fe summary ¼ ﬁxed effects summary statistic, re summary ¼ random effects summary statistic. The inter-study heterogeneity I2 is
shown along with the corresponding signiﬁcance level for each ﬁxed effects estimate. The statistical signiﬁcance for ﬁxed and random effects summary statistics is also shown.
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meta/index.html).
Adjustment for multiple comparisons
A Bonferroni cut-off of P< 0.002 (0.05/(3 biomarkers 8 traits))
was used.
ROC analysis
In order to assess the discriminating power of the biochemical
markers studied we generated ROC curves using knee incidence
and knee progression as outcomes in each of the four cohorts.
Results
Study participant characteristics
The descriptive characteristics of study participants are pre-
sented in Table I along with the number of cases for the outcomesinvestigated. The mean and SD for the three biochemical markers
are also shown for each cohort.Association between the biomarkers and OA traits
In the univariate analysis of the eight traits very strong associ-
ations were found between sCOMP and uCTX-II with most of the
traits studied with the exception of hip severity (Table II). After
adjustment for covariates sCOMP remained signiﬁcantly
(P < 0.002) associated only with risk of knee OA whereas uCTX-II
remained associated with risk of hand OA, of hip OA, of knee OA,
with progression and severity of knee OA (Table II). None of the
traits was associated at the Bonferroni level with C2M levels before
or after adjustment for covariates (Table II).
We investigated inter-study heterogeneity and found that
although signiﬁcant heterogeneity exists between studies for some
of these traits they remain statistically signiﬁcant even when
CTX-II and  risk of hand OA
1 2 5 10 100
re summary 4.98 (2.61, 9.47)
fe summary
I2=61% p<0.053
5.01 (3.36, 7.46)
Rotterdam 11.02 (5.23, 23.22)
GARP 4.85 (1.90, 12.36)
TwinsUK 4.57 (2.06, 10.11)
Chingford 2.49 (1.17, 5.28)
B CTX-II and risk of hip OA
5.21 (1.22, 22.20)
4.35 (2.39, 7.85)
GARP 20.77 (6.00, 71.91)
Rotterdam 8.31 (2.36, 29.32)
TwinsUK 5.74 (1.49, 22.14)
Chingford 0.83 (0.30, 2.31)
fe summary 
I =83% p<0.0006
re summary
C CTX-II and severity of knee OA
1 2 5 10 100 1000
5.70 (3.32, 9.87)
23.52 (3.26, 169.97)
5.42 (1.25, 23.54)
4.23 (2.10, 8.52)
8.75 (2.56, 29.96)
fe summary 
I =4% p<0.37
Rotterdam
GARP
TwinsUK
Chingford
D CTX-II and progression of knee OA
0.5 1 2 5 10 100
re summary 3.28 (1.56, 6.91)
fe summary
I =62% p<0.05
2.75 (1.77, 4.22)
TwinsUK 4.41 (1.28, 15.19)
GARP 6.99 (2.50, 19.51)
Rotterdam 3.62 (1.49, 8.80)
Chingford 1.46 (0.77, 2.75)
p=0.0018
p=5.1 x 10[-6]
p=0.026
p=1.6 x 10[-6]p=2.2 x 10[-15]
p=2.6 x 10[-10]
odds ratioodds ratio
odds ratioodds ratio
A
p=4.7 x 10[-7]
Fig. 2. Forest plot of study-speciﬁc estimates and ﬁxed effects summary OR estimates and 95% conﬁdence intervals (95%CIs) for the association between urinary CTXII and (A)
prevalence of hand OA (B) prevalence of hip OA (C) radiographic severity of knee OA (D) progression of knee OA. fe summary ¼ ﬁxed effects summary statistic, re
summary ¼ random effects summary statistic. The inter-study heterogeneity I2 is shown along with the corresponding signiﬁcance level for each ﬁxed effects estimate. The
statistical signiﬁcance for ﬁxed and random effects summary statistics is also shown.
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of risk of hip OA [Fig. 2(B)].
As one of the unmet medical needs concerning OA is being able
to identify which patients will progress to severe OAwe decided to
focus on progression of knee OA to perform a receiver operating
characteristics (ROC) analysis. Three models were ﬁtted with knee
OA progression as the outcome, model 1 consisted only of
anthropometric age, gender and BMI, model 2 included only uCTX-
II and model 3 included age, gender, BMI, and uCTX-II (Table III). InTable III
ROC analysis in four study cohorts for the use of uCTX-II levels in predicting progression
includes only age, gender and BMI, Model 2 includes only uCTX-II andModel 3 includes ag
cut-off of log10 uCTX2<2.6 (0) or 2.6, Model 5 includes age, gender, BMI and uCTXII as
Model 1 Model2 Model 3
Age þ BMI þ(sex) uCTX-II Age þ BMI þ(sex)þ
uCTX-II
Cohort AUC 95% CI AUC 95% CI AUC 95% CI
GARP 0.636 (0.56e0.71) 0.628 (0.56e0.7) 0.672 (0.60e0.74)
Rotterdam 0.696 (0.65e0.75) 0.607 (0.55e0.67) 0.706 (0.66e0.76)
Chingford 0.657 (0.62e0.7) 0.601 (0.56e0.65) 0.669 (0.63e0.71)
TwinsUK 0.599 (0.53e0.67) 0.615 (0.55e0.69) 0.626 (0.56e0.7)
Average 0.647 0.613 0.668none of the cohorts studied are the anthropometric traits alone or
uCTX-II alone sufﬁcient to reach a clinical usefulness (AUC< 0.7). In
all the four cohorts the addition of uCTX-II improves prediction of
radiographic knee OA progression.
One of the problems that has hindered the evaluation of
markers of OA has been the lack of a threshold level set for the
marker to classify patients has having or not having a positive or
negative result. A survival regression analysis taking the uCTX-II
levels as the time-dependent variable on OA progression wasof knee OA. The AUC for three models is shown for all four study cohorts. Model 1
e, gender, BMI and uCTX-II, Model 4 includes uCTX2 alone as a binary variable using a
a binary variable
AUC difference Model 4 Model 5 AUC difference
Log uCTXII  2.6 Age þ BMI þ(sex)þ
þlog uCTXII  2.6
Mod3eMod1 Mod5eMod1
0.037 0.525 (0.45e0.60) 0.643 (0.57e0.71) 0.007
0.010 0.560 (0.50e0.62) 0.705 (0.66e0.75) 0.009
0.012 0.570 (0.54e0.60) 0.683 (0.64e0.72) 0.026
0.027 0.533 (0.49e0.57) 0.612 (0.54e0.68) 0.013
0.021 0.547 0.661 0.014
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BMI). Based on these data it appeared that a threshold of log10
uCTX-II should be somewhere between 2.5 and 2.8 should be used
for radiographic progression (not shown). We tested cut-offs of
log10 uCTX-II uCT2.55, 2.60, 2.65, 2.70 and 2.80 (including age,
gender and BMI as covariates) in all four cohorts. Results were
meta-analysed across all cohorts resulting in OR(cut-off ¼ 2.55) ¼ 1.61
(95%CI 1.25e2.09 P ¼ 0.00026), OR(cut-off ¼ 2.60) ¼ 1.78 (95%CI 1.35e
2.36 P ¼ 5  105), OR(cut-off ¼ 2.65) ¼ 1.66 (95%CI 1.21e2.26
P¼ 0.0015), OR(cut-off ¼ 2.70)¼ 1.75 (95%CI 1.23e2.50 P¼ 0.002), and
OR(cut-off ¼ 2.80) ¼ 1.61 (95%CI 1.04e2.51 P ¼ 0.034). Having iden-
tiﬁed a log10 uCTXII cut-off of 2.60 as the best for progression of
knee OA, ROC analyses were performed using this cut-off alone
(Model 4, Table III) and with age, gender and BMI (Model 5,
Table III). The performance alone of this binary cut-off in a ROC
analysis is much inferior to the actual uCTX-II levels, but in com-
bination to age, BMI and gender results are similar to the quanti-
tative variable (Table III).
Discussion
In this study we have analysed the largest sample to date with
regards to biochemical markers of cartilage degradation. We
conﬁrm the value of uCTX-II as a degradation product that corre-
lates with a vast number of OA traits, namely hip knee and hand OA
in addition to knee OA progression and radiographic severity of
knee OA. On the other hand, although COMP and C2M are strongly
correlated with some of the OA traits studied here, the associations
become very weak or non-signiﬁcant when adjustments for age,
gender and BMI are performed.
The analyses carried out also highlight the challenges of using
biochemical markers for prognostic uses. It is commonly accepted
that a clinically useful diagnostic should have an AUC of 0.7 or
higher and a high accuracy diagnostic of 0.9 or higher19. The results
from the four study cohorts show that cartilage degradation
markers do not achieve such predictive values yet neither alone or
in combination with anthropometric characteristics. On the other
hand, they form the basis onto which it may be possible to add
other biochemical or imaging or molecular markers that may
improve prediction.
An observation worth of note is that uCTX-II, but not C2M was
strongly associated with the OA traits, although both are products
of type II collagen degradation2,3. Recent studies have shown that
there may be a difference in origin of the two type II collage
markers. Immunolocalization studies have shown that CTX-II is
highly associated with calciﬁed cartilage remodelling as well as
ﬁbrillation of the cartilage20, whereas C2M seems to be present in
the core of the articular cartilage2. This is supported by studies
showing a strong association between uCTX-II and clinical features
such as joint space narrowing, pain, osteophyte formation and
subchondral bone remodelling21. A recent cluster analysis has
shown a relationship between uCTX-II and bone resorption
markers further supporting a strong association of uCTX-II with
calciﬁed cartilage. Interesting we did see aweak association of C2M
with knee OA incidence and progression to a similar degree as CTX-
II, which may indicate connection to knee OA. C2M is yet another
novel marker which needs to be further validated in studies with
cartilage measures. Another observation worth of note is that our
results conﬁrm a role for sCOMP as a biomarker for knee OA but not
hip OA as has been recently reported22.
The current study has some limitations that must be taken into
account. The results from C2M combine data from serum (Rotter-
dam, TwinsUK and Chingford) and from urine (GARP). Thus
although the combined data are not signiﬁcant the heterogeneity
introduced by the two types of biospecimen may have reduced ourstatistical power to detect strong associations with OA. More
importantly, two of the population-based cohorts consist only of
females, and the GARP study is also biased towards a large pro-
portion of females. Other limitations include the fact our study is
based on K/L grades which conﬂate osteophyte and joint space
narrowing and some studies have shown that biomarker associa-
tions can be different with respect to these related but different
features23. Finally the study has not investigated other joints, e.g.,
facet joints in the spine, nor have we carried out a number of sub-
analyses which may reveal stronger or weaker biomarker associa-
tions. Speciﬁcally, although all analyses are adjusted for BMI, we
have not explored the role of biomarkers within the obese
population.
Nonetheless, the current study is the largest by far in its kind
and shows that biomarkers can be valuable prognostic tools for
progression of knee OA. However these data also highlight is a need
for more biomarkers to achieve sufﬁcient value to predict OA pro-
gression in the clinic.
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